<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>pharmacology and therapeutics</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>pharmacology and therapeutics | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.
Authors: Yang, G.; Alarcon, C.; Chanfreau-Coffinier, C.; Lee, N. H.; Friedman, P.; Nutescu, E.; Tuck, M.; O&#39;Brien, T.; Gong, L.; Klein, T. E.; Chang, K.-M.; Tsao, P. S.; Meltzer, D. O.; Million Veteran Program, ; Tuteja, S.; Perera, M. A.
Score: 1.8, Published: 2023-12-07 DOI: 10.1101/2023.12.05.23299140
Clopidogrel, an anti-platelet drug, used to prevent thrombosis after percutaneous coronary intervention.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="pharmacology and therapeutics" />
<meta property="og:description" content="Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.
Authors: Yang, G.; Alarcon, C.; Chanfreau-Coffinier, C.; Lee, N. H.; Friedman, P.; Nutescu, E.; Tuck, M.; O&#39;Brien, T.; Gong, L.; Klein, T. E.; Chang, K.-M.; Tsao, P. S.; Meltzer, D. O.; Million Veteran Program, ; Tuteja, S.; Perera, M. A.
Score: 1.8, Published: 2023-12-07 DOI: 10.1101/2023.12.05.23299140
Clopidogrel, an anti-platelet drug, used to prevent thrombosis after percutaneous coronary intervention." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-12-24T10:38:02+00:00" />
<meta property="article:modified_time" content="2023-12-24T10:38:02+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="pharmacology and therapeutics"/>
<meta name="twitter:description" content="Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.
Authors: Yang, G.; Alarcon, C.; Chanfreau-Coffinier, C.; Lee, N. H.; Friedman, P.; Nutescu, E.; Tuck, M.; O&#39;Brien, T.; Gong, L.; Klein, T. E.; Chang, K.-M.; Tsao, P. S.; Meltzer, D. O.; Million Veteran Program, ; Tuteja, S.; Perera, M. A.
Score: 1.8, Published: 2023-12-07 DOI: 10.1101/2023.12.05.23299140
Clopidogrel, an anti-platelet drug, used to prevent thrombosis after percutaneous coronary intervention."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "pharmacology and therapeutics",
      "item": "https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "pharmacology and therapeutics",
  "name": "pharmacology and therapeutics",
  "description": "Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.\nAuthors: Yang, G.; Alarcon, C.; Chanfreau-Coffinier, C.; Lee, N. H.; Friedman, P.; Nutescu, E.; Tuck, M.; O\u0026#39;Brien, T.; Gong, L.; Klein, T. E.; Chang, K.-M.; Tsao, P. S.; Meltzer, D. O.; Million Veteran Program, ; Tuteja, S.; Perera, M. A.\nScore: 1.8, Published: 2023-12-07 DOI: 10.1101/2023.12.05.23299140\nClopidogrel, an anti-platelet drug, used to prevent thrombosis after percutaneous coronary intervention.",
  "keywords": [
    
  ],
  "articleBody": " Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.\nAuthors: Yang, G.; Alarcon, C.; Chanfreau-Coffinier, C.; Lee, N. H.; Friedman, P.; Nutescu, E.; Tuck, M.; O'Brien, T.; Gong, L.; Klein, T. E.; Chang, K.-M.; Tsao, P. S.; Meltzer, D. O.; Million Veteran Program, ; Tuteja, S.; Perera, M. A.\nScore: 1.8, Published: 2023-12-07 DOI: 10.1101/2023.12.05.23299140\nClopidogrel, an anti-platelet drug, used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic episodes, with African Americans suffering disproportionately. The aim of this study was to identify biomarkers of clopidogrel resistance in African American patients. We conducted a genome-wide association study, including local ancestry adjustment, in 141 African Americans on clopidogrel to identify associations with high on-treatment platelet reactivity (HTPR). We validated genome-wide and suggestive hits in an independent cohort of African American clopidogrel patients (N = 823) from the Million Veterans Program (MVP) along with in vitro functional follow up. We performed differential gene expression (DGE) analysis in whole blood with functional follow-up in MEG-01 cells. We identified rs7807369, within thrombospondin 7A (THSD7A), as significantly associated with increasing risk of HTPR (p = 4.56 x 10-9). Higher THSD7A expression was associated with HTPR in an independent gene expression cohort of clopidogrel treated patients (p = 0.004) and supported by increased gene expression on THSD7A in primary human endothelial cells carrying the risk haplotype. Two SNPs (rs1149515 and rs191786) were validated in the MVP cohort. DGE analysis identified an association with decreased LAIR1 expression to HTPR. LAIR1 knockdown in a MEG-01 cells resulted in increased expression of SYK and AKT1, suggesting an inhibitory role of LAIR1 in the Glycoprotein VI pathway. Notably, the CYP2C19 variants showed no association with clopidogrel response in the discovery or MVP cohorts. In summary, these finding suggest that other variants outside of CYP2C19 star alleles play an important role in clopidogrel response in African Americans. Key PointsSNPs within THSD7A were associated to clopidogrel resistance in African Americans. THSD7A gene expression is higher in patients with clopidogrel resistance and in endothelial cells carrying the risk variants. No association to high on therapy platelet reactivity or major adverse cardiac events was seen with CYP2C19 star alleles in either the African American cohort investigated. Decreased LAIR1 gene expression in blood was associated to risk of HTPR and showed downstream effect on SKY and AKT.\n",
  "wordCount" : "390",
  "inLanguage": "en",
  "datePublished": "2023-12-24T10:38:02Z",
  "dateModified": "2023-12-24T10:38:02Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      pharmacology and therapeutics
    </h1>
    <div class="post-meta">&lt;span&gt;updated on December 24, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.12.05.23299140">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.12.05.23299140" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.12.05.23299140">
        <p class="paperTitle">Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.12.05.23299140" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.12.05.23299140" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Yang, G.; Alarcon, C.; Chanfreau-Coffinier, C.; Lee, N. H.; Friedman, P.; Nutescu, E.; Tuck, M.; O&#39;Brien, T.; Gong, L.; Klein, T. E.; Chang, K.-M.; Tsao, P. S.; Meltzer, D. O.; Million Veteran Program,  ; Tuteja, S.; Perera, M. A.</p>
        <p class="info">Score: 1.8, Published: 2023-12-07 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.12.05.23299140' target='https://doi.org/10.1101/2023.12.05.23299140'> 10.1101/2023.12.05.23299140</a></p>
        <p class="abstract">Clopidogrel, an anti-platelet drug, used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic episodes, with African Americans suffering disproportionately. The aim of this study was to identify biomarkers of clopidogrel resistance in African American patients.

We conducted a genome-wide association study, including local ancestry adjustment, in 141 African Americans on clopidogrel to identify associations with high on-treatment platelet reactivity (HTPR). We validated genome-wide and suggestive hits in an independent cohort of African American clopidogrel patients (N = 823) from the Million Veterans Program (MVP) along with in vitro functional follow up. We performed differential gene expression (DGE) analysis in whole blood with functional follow-up in MEG-01 cells.

We identified rs7807369, within thrombospondin 7A (THSD7A), as significantly associated with increasing risk of HTPR (p = 4.56 x 10-9). Higher THSD7A expression was associated with HTPR in an independent gene expression cohort of clopidogrel treated patients (p = 0.004) and supported by increased gene expression on THSD7A in primary human endothelial cells carrying the risk haplotype. Two SNPs (rs1149515 and rs191786) were validated in the MVP cohort. DGE analysis identified an association with decreased LAIR1 expression to HTPR. LAIR1 knockdown in a MEG-01 cells resulted in increased expression of SYK and AKT1, suggesting an inhibitory role of LAIR1 in the Glycoprotein VI pathway. Notably, the CYP2C19 variants showed no association with clopidogrel response in the discovery or MVP cohorts.

In summary, these finding suggest that other variants outside of CYP2C19 star alleles play an important role in clopidogrel response in African Americans.

Key PointsSNPs within THSD7A were associated to clopidogrel resistance in African Americans.

THSD7A gene expression is higher in patients with clopidogrel resistance and in endothelial cells carrying the risk variants.

No association to high on therapy platelet reactivity or major adverse cardiac events was seen with CYP2C19 star alleles in either the African American cohort investigated.

Decreased LAIR1 gene expression in blood was associated to risk of HTPR and showed downstream effect on SKY and AKT.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
